American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors
This article provides a review of approaches to challeng ing dermatologic considerations associated with immune checkpoint inhibitor therapies. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 16, 2022 Category: Dermatology Source Type: research

Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments
AbstractGeneralized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease characterized by sudden widespread eruption of sterile pustules with or without systemic symptoms. GPP may be life threatening in cases with severe complications such as cardiovascular failure, acute respiratory distress syndrome, and serious infections. Impetigo herpetiformis (IH) is a GPP that is induced and exacerbated by pregnancy and occurs most frequently during the last trimester. IH may result in poor or fatal neonatal outcomes, including placental insufficiency, fetal abnormalities, stillbirth, and early neonatal death. Most p...
Source: American Journal of Clinical Dermatology - June 15, 2022 Category: Dermatology Source Type: research

JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
AbstractJanus kinase (JAK) inhibitors are immunomodulatory agents with broad potential for use within dermatology. However, the US Food and Drug Administration has recently placed additional warning labels on JAK inhibitors given concern for an increased risk of major adverse cardiovascular events, malignancy, venous thromboembolism, and mortality. Here, we summarize recent efficacy and safety data of multiple JAK inhibitors including tofacitinib, upadacitinib, baricitinib, and abrocitinib. JAK inhibitors have high efficacy in treating psoriatic arthritis and atopic dermatitis, but carry an increased risk of ven ous thro...
Source: American Journal of Clinical Dermatology - June 9, 2022 Category: Dermatology Source Type: research

Author ’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 4, 2022 Category: Dermatology Source Type: research

Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 4, 2022 Category: Dermatology Source Type: research

Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice
AbstractAtopic dermatitis (AD) is characterized by a heterogenous longitudinal course with varying severity, flares, and persistence. However, AD course is not routinely assessed in clinical practice or controlled trials. Our objective was to review the longitudinal course of AD in children and adults and discuss implications for routine practice and clinical trials. We conducted a focused review of the published literature, including retrospective, prospective, and interventional studies, clinical trials, and consensus guidelines. Estimates of AD persistence varied widely across studies but suggested that AD can indeed pe...
Source: American Journal of Clinical Dermatology - May 31, 2022 Category: Dermatology Source Type: research

Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments
AbstractPyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target. T helper 17/T helper 1-skewed inflammation and exaggerated inflammasome activation lead to a dysregulated neutrophil-domi...
Source: American Journal of Clinical Dermatology - May 24, 2022 Category: Dermatology Source Type: research

Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review
AbstractGenodermatoses are genetically inherited dermatologic conditions. The management of cutaneous findings in genodermatoses is challenging, and first-line therapies, such as steroids and/or retinoids, are often inadequate. In recent years, research on the molecular basis of genodermatoses has led to the use of biologic therapies for intractable disease. Here, we review the evidence regarding the use of available biologic therapies for the management of dermatologic findings in genodermatoses. Biologic therapies appear to be promising therapeutic options for several recalcitrant genodermatoses, especially those with un...
Source: American Journal of Clinical Dermatology - May 23, 2022 Category: Dermatology Source Type: research